ADMA
Adma Biologics, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$11.41Close
$2.7BMarket cap
$7.60 – $20.3852-week range
Nov 4, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 47 · weaker than 53% of stocks over 12 months
- Far from its high 44% below its 52-week high
- Extended 4.2 ATR above its 50-day average
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
44%
1wk
up 6.8%
price change
1mo
up 13.8%
price change
12-month return
down 25%
market up 11% ·
its own down 37%
F-score
5 / 9
Mixed
Altman Z
13.31
Low risk
P/E
18.5×
price / earnings
PEG
—
P/E / EPS growth
P/B
5.7×
price / book
Earnings yield
up 7.1%
EBIT / enterprise value
Cheaper than
47%
of the market · around average
Revenue growth
up 20%
year on year
EPS growth
up 19%
latest quarter · -52 pts
Sales growth
up 2%
latest quarter · +2 pts
ROE
up 36%
return on equity
Free cash margin
up 5%
$27.8M FCF
D/E
0.15
long-term debt / equity
Net debt / EBITDA
-0.1×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- profitability slipped from last year
- profits not fully backed by cash
- issued more shares
- assets working less efficiently
- profitable on its assets
- generating cash from operations
- reduced long-term debt
- short-term liquidity improved
- gross margin widened
Repair signals
- Gross margin 51.5% → 57.4%
Trade setup
ATR%
3.4%
$0.38 a day · 2×ATR $10.64
RS
47 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
1.22
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: fails
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: passes
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Profit not backed by cash Reported profit of $146.9M came with $50.4M of operating cash flow. Profit that cash does not follow is the classic signature of aggressive accounting.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+13% vs market2 sessions after results
Financials
- Gross 57%
- Net 29%
- Free cash 5%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $42.2M | $80.9M | $154.1M | $258.2M | $426.5M | $510.2M |
| Gross margin | -45% | 1% | 23% | 34% | 51% | 57% |
| Operating income | -$64.9M | -$58.4M | -$39.4M | $21.6M | $139.0M | $191.4M |
| Net income | -$75.7M | -$71.7M | -$65.9M | -$28.2M | $197.7M | $146.9M |
| Net margin | -179% | -89% | -43% | -11% | 46% | 29% |
| Earnings per share | -$0.88 | -$0.51 | -$0.33 | -$0.13 | $0.81 | $0.60 |
| Free cash flow | -$114.7M | -$125.9M | -$73.4M | $4.0M | $110.4M | $27.8M |
| Free cash margin | -272% | -156% | -48% | 2% | 26% | 5% |
| Cash | $55.9M | $51.1M | $86.5M | $51.4M | $103.1M | $87.6M |
| Long-term debt | $100.0M | $94.9M | $142.8M | $130.6M | $72.3M | $69.3M |
| Shareholders' equity | $88.2M | $141.2M | $152.0M | $135.2M | $349.0M | $477.3M |
| Shares outstanding | 104.90m | 195.81m | 221.82m | 226.06m | 236.62m | 237.87m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 25, 2026 | Annual ↗ | Dec 31, 2025 | 56d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Mar 18, 2025 | Annual ↗ | Dec 31, 2024 | 77d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 5, 2026 | Results ↗ |
| Jun 2, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| May 4, 2026 | Other events ↗ |
| Mar 27, 2026 | Regulation FD ↗ |
| Mar 2, 2026 | Regulation FD · Other events ↗ |
| Feb 25, 2026 | Results · Director or officer change ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |
| Nov 5, 2025 | Results ↗ |
| Aug 6, 2025 | Material agreement · Agreement ended · Results · New obligation ↗ |
| Jun 4, 2025 | Shareholder vote ↗ |
| May 7, 2025 | Results · Other events ↗ |